Martin B. Leon Center for Cardiovascular Transformation Announced

October 14, 2020

Martin B. Leon Center for Cardiovascular Transformation: The American College of Cardiology and the Cardiovascular Research Foundation are partnering to create the Martin B. Leon Center for Cardiovascular Transformation, a visionary endeavor designed to foster the best ideas, encourage innovative research, and ultimately deliver transformative solutions to some of the biggest cardiovascular care challenges.

Martin B. Leon Center for Cardiovascular Transformation is inspired by Martin Leon, MD, FACC, and his legacy of innovation in cardiovascular care. Leon is a distinguished pioneer in interventional cardiology and the founder and director of Transcatheter Cardiovascular Therapeutics (TCT), a leading scientific symposium dedicated to interventional cardiovascular medicine.

“Designed to foster the best ideas, encourage innovative research, and ultimately deliver transformative and global solutions to some of the biggest challenges facing our profession and our patients – the Leon Center will be as transformational as the man for which it is named,” said CRF President and CEO Juan F. Granada, MD. “CRF is excited to work with the ACC on this visionary endeavor that will build on the legacy already created by Dr. Martin Leon. The future of our profession and of our patients will be brighter because of this work together.”

Through the Leon Center’s four pillars, ACC and CRF will offer new advanced fellowships and clinical research grants focused on enhancing the pace of research in order to eradicate health disparities and transform cardiovascular care. The four pillars are:

  • Addressing the impact of the pandemic on cardiovascular research and care.
  • Programs to impact workforce diversity and team-based care.
  • Workshops and forums to promote innovations in cardiovascular care.
  • Patient advocacy and patient-centered education and research programs with a focus on underserved populations.

“To improve cardiovascular care and outcomes, we need visionary thinking and bold action. Through our joint work to create the Martin B. Leon Center for Cardiovascular Transformation, the ACC and CRF promise to deliver on that vision.” said ACC President Athena Poppas, MD, FACC. “The biggest challenges require collaborative solutions, and through the Leon Center we are fostering diversity, innovative research and leadership as a springboard to a healthier future.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”